Expert Strategies to Optimize the Treatment of Patients With Squamous NSCLC
Source: Expert Strategies to Optimize the Treatment of Patients With Squamous NSCLC

Video Module

In this on-demand Webcast from the 2017 CCO squamous NSCLC live meeting series, Paul K. Paik, MD, provides expert perspective on the optimal treatment of patients with advanced squamous NSCLC including discussion of the most recent clinical data and emerging therapeutic strategies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment strategies for patients with newly diagnosed squamous NSCLC
  • Incorporate current evidence-based treatment recommendations into the care of patients with metastatic squamous NSCLC that has progressed on or after frontline therapy
  • Discuss promising investigational agents and emerging therapeutic strategies with patients with squamous NSCLC based on an understanding of available clinical data and ongoing clinical trials
CCO Video Modules contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
 

Program Directors

  • Edward S. Kim
    MD
    Mark A. Socinski
    MD

Faculty

  • Paul K. Paik
    MD

Credit Information

  • Release Date:
    December 18, 2017
  • Expiration Date:
    December 17, 2018
  • Physicians:
    maximum of 0.75 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

 

Program Directors

Edward S. Kim, MD

Chair, Solid Tumor Oncology and Investigational Therapeutics
Solid Tumor Oncology
Levine Cancer Institute/Carolinas Healthcare System
Charlotte, North Carolina

Edward S. Kim, MD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Celgene, and Lilly.

 

Mark A. Socinski, MD

Executive Medical Director
Member,
Thoracic Oncology Program
Florida Hospital Cancer Institute
Orlando, Florida

Mark A. Socinski, MD, has disclosed that he has received fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from Bristol-Myers Squibb, Celgene, Genentech, and Lilly and funds for research support from Celgene, Genentech, and Pfizer.

 

Faculty

Paul K. Paik, MD


Assistant Attending
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Paul K. Paik, MD, has disclosed that he has received consulting fees from Celgene and Lilly and funds for research support from Celgene.
 

Staff

Rachael M. Andrie, PhD


Associate Managing Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
 

Timothy A. Quill, PhD


Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
 

Gordon Kelley, 


Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
 

Kevin Obholz, PhD


Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles W. Willis, MBA, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower receives consulting fees from Pfizer; Amanda Sewell, MBA, Manager of Continuing Education, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This activity is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who care for patients with non-small-cell lung cancer.


Goal

The goal of this activity is to improve participants’ competence in providing optimal care for patients with squamous non-small-cell lung cancer.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment strategies for patients with newly diagnosed squamous NSCLC
  • Incorporate current evidence-based treatment recommendations into the care of patients with metastatic squamous NSCLC that has progressed on or after frontline therapy
  • Discuss promising investigational agents and emerging therapeutic strategies with patients with squamous NSCLC based on an understanding of available clinical data and ongoing clinical trials
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, and Lilly.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 18, 2017, through December 17, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.